AstraZeneca announced that its investigational breast cancer treatment, trastuzumab deruxtecan, will undergo priority review by the FDA. The treatment was developed to treat HER2-positive metastatic breast cancer.
FDA grants priority review for AstraZeneca candidate for breast cancer
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.